02.01.2013 Views

Speakers - Sachs Associates

Speakers - Sachs Associates

Speakers - Sachs Associates

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

CONTACTS<br />

Aaron Powers<br />

President<br />

Dave Reusswig<br />

Vice President<br />

ADDRESS<br />

3820 Ohio Ave, Ste 8-14<br />

St Charles, IL 60174<br />

TELEPHONE<br />

630-400-2135<br />

FAX<br />

480-287-8984<br />

EMAIL<br />

aapowers@mac.com<br />

YEAR FOUNDED<br />

2007<br />

Northern Biotechnologies llc<br />

www.nothernbiotechnologies.com<br />

FINANCIAL SUMMARY<br />

Northern Biotechnologies has raised $1.5M in round “a” private funding. Northern is seeking commercialization<br />

and investment partnerships to continue the development of additional anti-bacterial, antiviral and anti-fungal<br />

applications of our technology which require additional testing, proof of concept and commercialization partners.<br />

COMPANY PROFILE<br />

Northern Biotechnologies is pioneering the commercialization of an innovative, long lasting, therapeutic anti<br />

microbial technology that has significant applications in the Human Health Care arena. Infectious disease control<br />

and prevention can be revolutionized by integration of our cost saving technology. Issued Patents and proprietary<br />

production IP offer a stable platform for growth and partnership into all human related applications of the<br />

technology. A unique feature of the technology is its extended protection of 1-3 days through each application.<br />

Additionally, the physical method of pathogen destruction prevents formation of resistant strain types, in contrast<br />

to existing technologies that rely on metabolic action for kill. Testing shows high performance anti-bacterial,<br />

anti-fungal and antiviral functioning in various direct, topical, and wound care, nasal/ oral and related dosing<br />

mechanisms of the technology. We are in process with the first New Drug Application for antiseptic hand wash,<br />

and are looking for partners to pursue additional drug approvals in specific markets.<br />

Existing product branding in the Human market is Prefense hand sanitizer and wipes. In addition to human<br />

applications, Northern holds over twenty-five global patents for anti-microbial water filtration using our<br />

technology. We also hold EPA registrations for persistent antimicrobial filter media. Significant opportunity exists<br />

in the technology used as a multi surface sanitizer for all levels of food production. Other existing product lines<br />

and cash flow are in place from additional internally developed technologies including high performance filtration<br />

medias, biotech remediation and process technologies used in petroleum, agricultural, and industrial processing.<br />

Northern also holds nationally placed consumer and professional brand lines of “green probiotic” cleaning<br />

products based on our IP and manufacturing base. Additionally, our cGMP contract packaging division sells<br />

our proprietary formulations to many national brands in a variety of markets. Company management is made<br />

of a diverse team with the experience and drive required to steer strong growth and relationships with partner<br />

companies.<br />

MANAGEMENT<br />

Aaron Powers, President<br />

Dave Reusswig, Vice President<br />

Katan & <strong>Associates</strong>, Financial Consultants<br />

t back :: next u<br />

WELCOME PHARMA LICENSING GROUPS<br />

SPEAKERS<br />

PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />

ORGANISERS

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!